Please login to the form below

Not currently logged in

Recordati completes acquisition of Laboratorios Casen Fleet

Concludes €93m deal for Spanish gastroenterology specialist

Recordati has finalised its €93m deal to acquire Spanish pharmaceutical company Laboratorios Casen Fleet.

The agreement with the Madrid-headquartered gastroenterology specialist generates boosts Recordati's marketing strength in Spain and Portugal and increases its over-the-counter (OTC) footprint.

Around 55 per cent of Laboratorios Casen Fleet's revenues from products to help patients prepare for colonoscopy, led by the oral solution Citrafleet, which Recordati already markets in Germany.

Taking ownership of the company, which last year brought in sales of just over €45m, Recordati also gains access to several OTC gynaecology brands.

Approximately 80 per cent of Laboratorios Casen Fleet's revenue is generated by private payers and is therefore outside public healthcare reimbursement schemes.

In addition to its Madrid offices Laboratorios Casen Fleet also runs production facilities in Utebo, Zaragoza and employs around 230 people.

The deal continues Recordati's strategy of making bolt-on acquisitions. Last year it acquired Turkish pharmaceutical company Frik Ilaç and has followed this up with several further deals.

In January it agreed to pay $100m for a portfolio of products from Danish pharma company Lundbeck and later in the year took a 90 per cent stake in Tunisian pharma firm Opalia.

Article by
Dominic Tyer

22nd October 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...